中國醫藥學院(現中國醫藥大學)醫學系學士1986~1993

和信治癌中心醫院 血液與腫瘤科部 副主任 2020.02.01~2022.06.30
和信治癌中心醫院 血液與腫瘤科部 資深主治醫師 2003~2022

中華民國內科醫學會
中華民國癌症醫學會
台灣安寧緩和醫學會
美國臨床腫瘤醫學會
美國血液學會

ABSTRACT/PRESENTATION
• Chi-Feng Chung, Mei-Ching Liu, Skye H. Cheng, Chii-Ming Chen.　Leukemia after adjuvant chemotherapy for breast cancer: a case report and review of incidence in KF-SYSCC. The 7th Taiwan Joint Cancer Conference.
Chi-Feng Chung, Mei-Ching Liu, Chiang-Ching Shih.　Pseudomonas aeruginosa Bacteremia in Patients with Cancer. The 8th Taiwan Joint Cancer Conference.
• Lee S. Schwartzberg, Igor Bondarenko, Sara M. Tolaney, Andrew David Seidman, Joyce O''Shaughnessy, Yaroslav V. Shparyk, Chi-Feng Chung, Yen-Shen Lu, Nuria Chic, Lawrence C. Panasci, Yee Soo Chae, Sabela Recalde, Yevhen Hotko, Patricia Gomez, Gail Lynn Shaw Wright, Noshir Anthony Dacosta, Sina Vatandoust, Joseph P. O''Connell, Thomas Wei, Hope S. Rugo.　Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane. J Clin Oncol 39, 2021 (suppl 15; abstr 1061).
• J. Cortés, S. Kim, W. Chung, S. Im, Y.H. Park, R. Hegg, M.H. Kim, L. Tseng, V. Petry, C. Chung, H. Iwata, E. Hamilton, G. Curigliano, B. Xu, C. Lee, Y. Liu, J. Cathcart, E. Bako, S. Verma, S.A. Hurvitz. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. ESMO Congress 18 Sep 2021. Presidential symposium 1. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741.
• 2021 San Antonio Breast Cancer Symposium. Abstract GS3-01. Presented December 9, 2021. Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumabemtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase III study DESTINY-Breast03. Hurvitz S, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, Kim M-H, Tseng L-M, Petry V, Chung C-F, Iwata H, Hamilton E, Curigliano G, Xu B, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Cortés J.

PUBLICATIONS
• Yang PS, Lee YH, Chung CF, Chang YC, Wang MY, Lo C, Tsai LW, Shih KH, Lei J, Yu BL, Cheng SH, Huang CS.　A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer. Jpn J Clin Oncol. 2019 Dec 18;49(11):1029-1036.
• Penn IW, Chang YC, Chuang E, Chen CM, Chung CF, Kuo CY, Chuang TY.　Risk factors and prediction model for persistent breast-cancer-related lymphedema: a 5-year cohort study. Support Care Cancer. 2019 Mar;27(3):991-1000.
• Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. Javier Cortés, M.D., Ph.D., Sung-Bae Kim, M.D., Ph.D., Wei-Pang Chung, M.D., Seock-Ah Im, M.D., Ph.D., Yeon Hee Park, M.D., Ph.D., Roberto Hegg, M.D., Ph.D., Min Hwan Kim, M.D., Ph.D., Ling-Ming Tseng, M.D., Vanessa Petry, M.D., Chi-Feng Chung, M.D., Hiroji Iwata, M.D., Ph.D., Erika Hamilton, M.D., Giuseppe Curigliano, M.D., Ph.D., Binghe Xu, M.D., Ph.D., Chiun-Sheng Huang, M.D., Ph.D., M.P.H., Jee Hyun Kim, M.D., Ph.D., Joanne W.Y. Chiu, M.B., B.S., Jose Luiz Pedrini, M.D., Ph.D., Caleb Lee, M.D., Ph.D., Yali Liu, Ph.D., Jillian Cathcart, Ph.D., Emarjola Bako, M.D., Sunil Verma, M.D., and Sara A. Hurvitz, M.D.
N Engl J Med 2022; 386:1143-1154.
• Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cortés J. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open. 2024 May;9(5):102924.